Incannex Healthcare Ltd (IXHL) News

Form S-3 - Registration statement under Securities Act of 1933

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

NEW YORK and MELBOURNE, Australia, March 07, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq:...

Form 8-K - Current report

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL...

Form 8-K - Current report

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Demonstrated bioavailability of IHL-42X, Incannex’s proprietary combination formulation, confirming delivery of...

Form 8-K - Current report

Form 8-K - Current report